DMAC at a glance
DiaMedica Therapeutics Inc. (DMAC, SEC CIK 1401040) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on August 10, 2026 and Form 4 insider filings as recently as August 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 21 institutional investment managers tracked by SignalX reported holding DiaMedica Therapeutics Inc. (DMAC) shares worth $37.8 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 21 funds
- $37.8M · −1 vs prior quarter
- Latest 8-K
- Aug 10, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0; no product sales, with no commercial approval
- Net loss $8.9M for the quarter, versus no quarterly net-loss figure disclosed for 2025
- R&D expense $8.2M vs $5.8M YoY; G&A expense $2.3M vs $2.2M
- Cash, equivalents and securities $43.5M vs $59.9M at December 31, 2025; operating cash use $17.2M six months
- ReMEDy2 enrollment 85% toward interim analysis; slower activations and enrollment, with analysis estimated in first quarter 2027
Risk Factors
- No material risk-factor changes from the December 31, 2025 Form 10-K
- Carried-forward risks remain applicable to DiaMedica’s business, financial condition, and results
- Unknown or currently immaterial risks could impair future operating results
AI summary of the DMAC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Detailed results available in Exhibit 99.1 press release
Item 5.07: Submission of Matters to a Vote of Security Holders
- All seven incumbent directors re-elected, preserving board continuity through the next annual meeting
- Baker Tilly US, LLP ratified as independent auditor for fiscal 2026, with shareholders authorizing board-set remuneration
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 results for quarter ended March 31, 2026
- Press release attached as Exhibit 99.1 contains the financial results
AI summaries of DMAC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DMAC
Don't miss the next DMAC filing
- Alerts as it files. A push when DMAC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DMAC, by share count.
- Ask anything. An AI agent that reads every DMAC filing and answers with sources.
DMAC alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Pauls Dietrich John | A | Aug 10, 2026 | 60,200 | - |
| Kellen Scott | A | Jun 1, 2026 | 162,000 | - |
| Parsons James T. | A | Jun 1, 2026 | 51,189 | - |
| Giuffre Randall Michael | A | Jun 1, 2026 | 40,412 | - |
| Kuntz Richard | A | Jun 1, 2026 | 40,412 | - |
| Krop Julie | A | Jun 1, 2026 | 67,500 | - |
| Lewis Tanya | A | Jun 1, 2026 | 40,412 | - |
| O'Connor Daniel J. | A | Jun 1, 2026 | 40,412 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$21.3M | -$26.7M | -$34.4M |
| Net Income | -$19.4M | -$24.4M | -$32.8M |
| Balance Sheet | |||
| Total Assets | $54.2M | $46.3M | $61.4M |
| Equity | $51.1M | $40.7M | $56.1M |
| ROE | -38.0% | -60.0% | -58.4% |
| Per Share | |||
| EPS | - | $-0.60 | $-0.70 |
| Cash Flow | |||
| Operating CF | -$18.7M | -$22.1M | -$29.1M |
| CapEx | $24K | $25K | $40K |
Source: XBRL data in DiaMedica Therapeutics Inc. (DMAC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate DMAC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 21 | $37.8M |
| Q1 2026 | 22 | $33.5M |
| Q4 2025 | 20 | $43.6M |
| Q3 2025 | 20 | $36.5M |
| Q2 2025 | 16 | $14.6M |
| Q1 2025 | 12 | $8.6M |
| Q4 2024 | 8 | $9.0M |
| Q3 2024 | 6 | $1.1M |
- BlackRock+396.1K (+21%)
- Goldman Sachs Group+108.8K (+183%)
- Vanguard Portfolio Management LLC+48.2K (+24%)
- Vanguard Capital Management LLC+22.1K (+7%)
- Wells Fargo & Co+21.0K (+131%)
- Millennium Management−90.3K (-10%)
- Morgan Stanley−58.5K (-56%)
- Northern Trust−11.0K (-3%)
- Invesco Ltd−5.1K (-21%)
- FMR LLC (Fidelity)−1.6K (-15%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 125 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
DMAC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 8-K | May 21, 2026 | - | Analysis | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 8-K | Mar 31, 2026 | - | - | - |
| 10-K | Mar 30, 2026 | Dec 31, 2025 | - | |
| 4 | Jan 6, 2026 | - | - | |
| 4 | Jan 6, 2026 | - | - | |
| 4 | Jan 6, 2026 | - | - | |
| 8-K | Jan 5, 2026 | - | - | |
| 8-K | Dec 18, 2025 | - | - | |
| 4 | Dec 8, 2025 | - | - | |
| 4 | Nov 25, 2025 | - | - | |
| 10-Q | Nov 12, 2025 | Sep 30, 2025 | Analysis |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
DMAC SEC filings: frequently asked questions
Which institutions hold DMAC stock?
As of June 30, 2026, the largest DiaMedica Therapeutics Inc. (DMAC) holders among the 13F filers tracked by SignalX were BlackRock ($15.9 million), Millennium Management ($6.0 million), State Street Corp ($4.6 million), Vanguard Capital Management LLC ($2.5 million), Northern Trust ($2.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did DMAC report in its latest 8-K?
DiaMedica Therapeutics Inc. (DMAC) filed an 8-K on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results announced for quarter ended June 30, 2026.
What are the latest DMAC SEC filings?
DiaMedica Therapeutics Inc. (DMAC) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on August 10, 2026, an 8-K current report on August 10, 2026 and a Form 4 insider filing on August 12, 2026.
What is DMAC's SEC CIK number?
DiaMedica Therapeutics Inc. (DMAC)'s SEC Central Index Key (CIK) is 1401040. EDGAR lists every DMAC filing under that number.
Ask anything about DMAC
The research agent reads DMAC's filings, financials, insider trades and 13F holders, then answers with sources.